Alkaline phosphatase and mortality in patients on peritoneal dialysis

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 4, 2014, Pages 771-778

  Liu, Xinhui ^a   Guo, Qunying ^a   Feng, Xiaoran ^a   Wang, Juan ^a   Wu, Juan ^a   Mao, Haiping ^a   Huang, Fengxian ^a   Yu, Xueqing ^a   Yang, Xiao ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; LANTHANUM CARBONATE; PARATHYROID HORMONE; SEVELAMER CARBONATE; BIOLOGICAL MARKER;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CARDIOVASCULAR MORTALITY; CHARLSON COMORBIDITY INDEX; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY TRANSPLANTATION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; RETROSPECTIVE STUDY; AGED; BLOOD; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHI SQUARE DISTRIBUTION; CHINA; ENZYMOLOGY; KAPLAN MEIER METHOD; KIDNEY DISEASES; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK; RISK ASSESSMENT; RISK FACTOR; TIME; UPREGULATION;

ADULT; AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; CHINA; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PERITONEAL DIALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UP-REGULATION;

EID: 84904492840     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08280813     Document Type: Article

References (28)

1. Tonelli M, Curhan G, Pfeffer M, Sacks F, Thadhani R, Melamed ML, Wiebe N, Muntner P: Relation between alkaline phospha-tase, serum phosphate, and all-cause or cardiovascular mortality. Circulation 120: 1784–1792, 2009.
2. Beddhu S, Ma X, Baird B, Cheung AK, Greene T: Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease. Clin J Am Soc Nephrol 4: 1805–1810, 2009.
3. Kovesdy CP, Ureche V, Lu JL, Kalantar-Zadeh K: Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD. Nephrol Dial Transplant 25: 3003–3011, 2010.
4. Taliercio JJ, Schold JD, Simon JF, Arrigain S, Tang A, Saab G, Nally JV Jr., Navaneethan SD: Prognostic importance of serum alkaline phosphatase in CKD stages 3-4 in a clinical population. Am J Kidney Dis 62: 703–710, 2013.
5. Blayney MJ, Pisoni RL, Bragg-Gresham JL, Bommer J, Piera L, Saito A, Akiba T, Keen ML, Young EW, Port FK: High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int 74: 655–663, 2008.
6. Regidor DL, Kovesdy CP, Mehrotra R, Rambod M, Jing J, McAllister CJ, Van Wyck D, Kopple JD, Kalantar-Zadeh K: Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 19: 2193–2203, 2008.
7. Beddhu S, Baird B, Ma X, Cheung AK, Greene T: Serum alkaline phosphatase and mortality in hemodialysis patients. Clin Nephrol 74: 91–96, 2010.
8. Pelletier S, Vilayphiou N, Boutroy S, Bacchetta J, Sornay-Rendu E, Szulc P, Arkouche W, Guebre-Egziabher F, Fouque D, Chapurlat R: Bone microarchitecture is more severely affected in patients on hemodialysis than in those receiving peritoneal dialysis. Kidney Int 82: 581–588, 2012.
9. Kong X, Zhang L, Zhang L, Chen N, Gu Y, Yu X, Liu W, Chen J, Peng L, Yuan W, Wu H, Chen W, Fan M, He L, Ding F, Chen X, Xiong Z, Zhang J, Jia Q, Shi W, Xing C, Tang X, Hou F, Shu G, Mei C, Wang L, Xu D, Ni Z, Zuo L, Wang M, Wang H: Mineral and bone disorder in Chinese dialysis patients: A multicenter study. BMC Nephrol 13: 116, 2012.
10. Delmez JA, Yan G, Bailey J, Beck GJ, Beddhu S, Cheung AK, Kaysen GA, Levey AS, Sarnak MJ, Schwab SJ; Hemodialysis (HEMO) Study Group: Cerebrovascular disease in maintenance hemodialysis patients: Results of the HEMO Study. Am J Kidney Dis 47: 131–138, 2006.
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40: 373–383, 1987.
12. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42[Suppl 3]: S1–S201, 2003.
13. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic KidneyDisease-MineralandBoneDisorder (CKD-MBD). Kidney Int Suppl 76: S1–S130, 2009.
14. Schoppet M, Shanahan CM: Role for alkaline phosphatase as an inducer of vascular calcification in renal failure? Kidney Int 73: 989–991, 2008.
15. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70: 771–780, 2006.
16. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K: Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 73: 1296–1302, 2008.
17. Lomashvili KA, Garg P, Narisawa S, Millan JL, O’Neill WC: Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: Potential mechanism for uremic vascular calcification. Kidney Int 73: 1024–1030, 2008.
18. Gallieni M, Caputo F, Filippini A, Gabella P, Giannattasio M, Stingone A, Farina M; ROCK-PD Study Investigators: Prevalence and progression of cardiovascular calcifications in peritoneal dialysis patients: A prospective study. Bone 51: 332–337, 2012.
19. Narisawa S, Harmey D, Yadav MC, O’Neill WC, Hoylaerts MF, Millán JL: Novel inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification. J Bone Miner Res 22: 1700–1710, 2007.
20. Cheung BM, Ong KL, Cheung RV, Wong LY, Wat NM, Tam S, Leung GM, Cheng CH, Woo J, Janus ED, Lau CP, Lam TH, Lam KS: Association between plasma alkaline phosphatase and C-reactive protein in Hong Kong Chinese. Clin Chem Lab Med 46: 523–527, 2008.
21. Kerner A, Avizohar O, Sella R, Bartha P, Zinder O, Markiewicz W, Levy Y, Brook GJ, Aronson D: Association between elevated liver enzymes and C-reactive protein: Possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 25: 193–197, 2005.
22. An X, Mao HP, Wei X, Chen JH, Yang X, Li ZB, Yu XQ, Li ZJ: Elevated neutrophil to lymphocyte ratio predicts overall and cardiovascular mortality in maintenance peritoneal dialysis patients. Int Urol Nephrol 44: 1521–1528, 2012.
23. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr., Tonelli M, Thadhani R: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72: 1004–1013, 2007.
24. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D’Agostino RB Jr., Haffner SM: Liver markers and development of the metabolic syndrome: The insulin resistance atherosclerosis study. Diabetes 54: 3140–3147, 2005.
25. Drechsler C, Verduijn M, Pilz S, Krediet RT, Dekker FW, Wanner C, Ketteler M, Boeschoten EW, Brandenburg V; NECOSAD Study Group: Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol 6: 1752–1759, 2011.
26. Filipowicz R, Greene T, Wei G, Cheung AK, Raphael KL, Baird BC, Beddhu S: Associations of serum skeletal alkaline phospha-tase with elevated C-reactive protein and mortality. Clin J Am Soc Nephrol 8: 26–32, 2013.
27. Price CP: Multiple forms of human serum alkaline phosphatase: Detection and quantitation. Ann Clin Biochem 30: 355–372, 1993.
28. Reust CE, Hall L: Clinical inquiries. What is the differential diagnosis of an elevated alkaline phosphatase (AP) level in an otherwise asymptomatic patient? J Fam Pract 50: 496–497, 2001.